Transepidermal water loss inhibitor

Abstract

To provide a novel percutaneous water evaporation inhibitor and a moisturizing agent using the same.SOLUTION: Provided are: 1. a percutaneous water evaporation inhibitor containing lactic acid bacteria derived from ivy vine as an active ingredient; 2. the percutaneous water evaporation inhibitor according to above 1, wherein the lactic acid bacteria derived from ivy vine are lactic acid bacteria and / or a variant thereof; 3. a rough skin improver containing the percutaneous water evaporation inhibitor according to above 1 or 2 as an active ingredient; 4. a moisturizing agent containing the percutaneous water evaporation inhibitor according to above 1 or 2 as an active ingredient; 5. a horny layer moisturizing and barrier protein (involucrin, filaggrin, and transglutaminase 1) expression promoter with the lactic acid bacteria derived from ivy vine and / or a variant thereof as an active ingredient.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a transepidermal water loss inhibitor. The present invention is widely used in foods and beverages, medicines, quasi-drugs, supplements, cosmetics, etc. [Background technology]

[0002] Maintaining and improving the condition of the skin is a concern for both men and women, regardless of time or age. Transepidermal water loss (TEWL), also known as TEWL, is used to evaluate the skin barrier, and a low TEWL is considered to be a high barrier.

[0003] In order to enhance the skin barrier, Patent Document 1 proposes a skin topical preparation containing an extract of a plant of the genus Prunus of the family Rosaceae as a substance that further enhances the TEWL suppressing effect of organically modified clay minerals. Patent Document 2 also proposes an oil-in-water emulsion composition as a substance that suppresses TEWL, which contains a propylene polymer having a weight average molecular weight of 25,000 to 100,000 and a melting point of 60°C to 100°C, a hydrocarbon oil having a melting point of less than 60°C, and an ester oil that is pasty at 25°C, in which the total oil amount is 5 to 20% by mass, and the content ratio of the above-mentioned paste-like ester oil to the total oil amount is 10 to 50% by mass (Patent Document 3).

[0004] Ulcerative colitis and Crohn's disease are inflammatory bowel diseases (IBDs) whose causes remain unclear and are difficult to treat. Factors involved in inflammatory bowel diseases include abnormalities in the intestinal flora, impaired secretory IgA production by intestinal epithelial cells, and cytokines under the intestinal mucosa (Patent Document 4). It is also known that Lactobacillus casei strain GG may increase IgA immune responses in the intestine, thereby enhancing the immunological barrier of the intestine, and it has also been reported that intranasal administration of Lactobacillus rhamnosus GG enhances cell-mediated immune responses in the respiratory tract, thereby protecting mice from influenza virus infection. This shows that IgA has a function of protecting against influenza infection and the like, and is also known to have a function of protecting against foreign viral substances in the oral cavity (Patent Document 4). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2007-153809 A [Patent Document 2] JP 2016-79183 A [Patent Document 3] JP 2018-177764 A [Patent Document 4] JP 2018-008980 A DISCLOSURE OF THEINVENTION [Problem to be solved by the invention]

[0006] Under such a background, the present inventors have found that lactic acid bacteria derived from kudzu vines have an effect of suppressing transepidermal water loss and promoting the expression of proteins for improving skin barrier function (expression levels of involucrin, filaggrin, and transglutaminase 1), and have completed the present invention. Furthermore, through clinical trials, they have found that the lactic acid bacteria have an effect of suppressing transepidermal water loss, improving collagen density, and increasing IgA, and have completed the present invention. That is, the present invention aims to provide a novel transepidermal water loss inhibitor, a skin barrier function improving protein expression promoter, an IgA increaser, and a collagen density improver, as well as a barrier improving agent using these. [Means for solving the problem]

[0007] The features of the present invention for solving the above problems are as follows. 1. A transepidermal water loss inhibitor whose active ingredient is lactic acid bacteria (Leuconostoc mesenteroides) derived from kudzu vines. 2. The transepidermal water loss inhibitor according to 1 above, characterized in that the lactic acid bacteria (Leuconostoc mesenteroides) derived from the kudzu vine is a lactic acid bacteria (Leuconostoc mesenteroides) strain (Patent Microorganisms Deposit Center Accession Number: NITE P-02751) and / or a mutant strain thereof. 3. A rough skin improving agent containing as an active ingredient the transepidermal water loss inhibitor described in 1 or 2 above. 4. A moisturizer containing as an active ingredient the transepidermal water loss inhibitor described in 1 or 2 above. 5. A stratum corneum moisturizing and barrier protein (involucrin, filaggrin, transglutaminase 1) expression promoter containing as an active ingredient a lactic acid bacteria (Leuconostoc mesenteroides) strain derived from kudzu vine (Patent Microorganisms Deposit Center Accession Number: NITE P-02751) and / or its mutant strain. 6. A dermal collagen density improving agent containing, as an active ingredient, a lactic acid bacteria (Leuconostoc mesenteroides) strain derived from kudzu vine (Patent Microorganisms Deposit Center Accession Number: NITE P-02751) and / or a mutant strain thereof. 7. A skin quality improving agent containing as an active ingredient a lactic acid bacteria (Leuconostoc mesenteroides) strain derived from kudzu vine (Patent Microorganisms Deposit Center Accession Number: NITE P-02751) and / or a mutant strain thereof. 8. An IgA enhancer containing as an active ingredient a lactic acid bacteria (Leuconostoc mesenteroides) strain derived from kudzu vine (Patent Microorganisms Deposit Center Accession Number: NITE P-02751) and / or a mutant strain thereof. [Brief description of the drawings]

[0008] [Figure 1]1 is a graph showing the transepidermal water loss inhibitory effect of "Kuzunotsuru lactic acid bacteria" (before application of SDS). [Diagram 2] 1 is a graph showing the transepidermal water loss inhibitory effect of "Kuzunotsuru lactic acid bacteria" (after application of SDS). [Diagram 3] 1 is a graph showing the inhibitory effect of "Kuzunotsuru lactic acid bacteria" on transepidermal water loss (amount of change before and after application of SDS). [Figure 4] 1 is a graph showing the transepidermal water loss inhibitory effect of "Kuzunotsuru Lactic Acid Bacteria" (the difference between the applied area and the unapplied area after SDS application). [Diagram 5] 1 is a graph showing the amount of involucrin mRNA expression in skin caused by "Kuzunotsuru lactic acid bacteria." [Figure 6] 1 is a graph showing the amount of skin filaggrin mRNA expression in "Kuzunotsuru Lactic Acid Bacteria." [Figure 7] 1 is a graph showing the amount of skin transglutaminase 1 mRNA expression in the case of "Kuzunotsuru Lactic Acid Bacteria." [Figure 8] The nucleic acid sequence of the 16S rDNA gene of the "Kuzunotsuru Lactobacillus" strain is shown. [Figure 9A] This is an alignment comparing the 16S rDNA gene of the "Kuzunotsuru Lactic Acid Bacteria" strain (the sequence of SIID23149-01 in the upper row) with the comparative Leuconostoc mesenteroides RIB.9186 strain (obtained from the National Research Institute of Brewing, the sequence of SIID23149-02 in the lower row). The 1243rd nucleic acid is "G" in SIID23149-01, whereas it is "A" in SIID23149-02 (shown separately in Figures 9A to 9C). [Figure 9B] This is an alignment comparing the 16S rDNA gene of the "Kuzunotsuru Lactic Acid Bacteria" strain (the sequence of SIID23149-01 in the upper row) with the comparative Leuconostoc mesenteroides RIB.9186 strain (obtained from the National Research Institute of Brewing, the sequence of SIID23149-02 in the lower row). The 1243rd nucleic acid is "G" in SIID23149-01, whereas it is "A" in SIID23149-02 (shown separately in Figures 9A to 9C). [Figure 9C] This is an alignment comparing the 16S rDNA gene of the "Kuzunotsuru Lactic Acid Bacteria" strain (the sequence of SIID23149-01 in the upper row) with the comparative Leuconostoc mesenteroides RIB.9186 strain (obtained from the National Research Institute of Brewing, the sequence of SIID23149-02 in the lower row). The 1243rd nucleic acid is "G" in SIID23149-01, whereas it is "A" in SIID23149-02 (shown separately in Figures 9A to 9C). [Figure 10] This is a simplified molecular phylogenetic tree based on the nucleic acid sequence of the 16S rDNA gene of the ``Kuzunotsuru Lactobacillus'' strain. [Figure 11] This is a graph showing the change in TEWL (cheek) between the placebo group and the lactic acid bacteria intake group in a clinical trial of ``Kuzunotsuru Lactic Acid Bacteria.'' [Figure 12] This is a graph showing the change in TEWL (arm) between the placebo group and the lactic acid bacteria intake group in a clinical trial of ``Kuzunotsuru Lactic Acid Bacteria.'' [Figure 13] This is a graph showing the change in saliva IgA in the placebo and lactobacillus intake groups in a clinical trial of "Kuzunotsuru lactobacillus" [Figure 14] This is a graph showing the change in DermaLab (collagen score) in a clinical trial of "Kuzunotsuru Lactic Acid Bacteria." DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The present invention will be described in detail below. The present invention is characterized by using lactic acid bacteria (Leuconostoc mesenteroides) derived from kudzu vines as an active ingredient.

[0010] Kudzu (Kuzu) is a creeping plant of the legume family, and its roots are widely used as the raw material for Chinese herbal medicines such as Kakkonto and as the raw material for kudzu starch, known as Yoshino kudzu. Kudzu flowers have also been used since ancient times as the raw material for Chinese herbal medicines, such as for preventing hangovers, the vines for kudzu cloth and handicrafts, and the leaves as livestock feed. The lactic acid bacteria (Leuconostoc mesenteroides) derived from kudzu vines are not particularly limited as long as they are obtained from kudzu vines, but the lactic acid bacteria (Leuconostoc mesenteroides) strain (Patent Microorganisms Deposit Center Accession Number NITE P-02751) and its mutant strains are preferred. This is because they have a more excellent effect of suppressing transepidermal water loss.

[0011] The lactic acid bacteria (Patent Microorganisms Depositary Center Accession Number: NITE P-02751) strain can be obtained by enriching and culturing the kudzu vines in a liquid medium for lactic acid bacteria containing antibiotics at 25°C to 37°C for 24 to 48 hours, smearing the resulting culture on a plate count agar medium containing BCP, and selecting five new vine strains (Patent Microorganisms Depositary Center Accession Number: NITE P-02751) belonging to Leuconostoc mesenteroides.

[0012] Typical culture conditions for the present lactic acid bacterium "Leuconostoc mesenteroides" (Patent Microorganisms Deposit Center Accession Number: NITE P-02751) isolated from kudzu vines (note that in this specification, the lactic acid bacterium with Patent Microorganisms Deposit Center Accession Number: NITE AP-02601 is also referred to as "Kuzunotsuru lactic acid bacterium") are static culture in MRS medium at 25 to 37°C for 24 to 48 hours, but are not limited thereto.

[0013] (Mycological characteristics) The novel "Kuzunotsuru lactic acid bacteria" (accession number NITE P-02751) belonging to Leuconostoc mesenteroides of the present invention has the following bacteriological characteristics characteristic of Leuconostoc mesenteroides and is used in fermented foods such as sauerkraut. This bacterium has the following bacteriological characteristics: - Gram-positive cocci in the form of chains or diplococci. They are classified into lactic acid bacteria and heterolactic acid bacteria that break down sugar and produce acetic acid, ethanol, CO2, and other short-chain fatty acids other than lactic acid bacteria. (Definition of terms) Listed below are definitions of terms specifically used in this specification. The term "heated cells" used herein refers to cells that have been heat-sterilized after cultivation. Typically, but not limited to, the term refers to cells that have been cultured at 20 to 40°C for 10 to 40 hours and then heat-sterilized at 70 to 121°C for 10 to 60 minutes.

[0014] A mutant strain of "Kuzunotsuru Lactic Acid Bacteria" can be prepared, for example, by carrying out a general mutation treatment, or by adaptation through successive culture or natural mutation. The mutation treatment can be carried out using a common mutagen. Examples of mutagens include drugs having mutagenic activity, ultraviolet light, etc. Examples of drugs having mutagenic activity include streptomycin, ofloxacin, ethyl methanesulfonate, nucleotide base analogues such as N-methyl-N'-nitro-N-nitrosoguanidine, bromouracil, and acridines.

[0015] The transepidermal water loss inhibitor of the present invention can be used as an ingredient of various foods and beverages. Examples of foods and beverages include general foods such as confectionery (gum, candy, caramel, chocolate, cookies, snacks, jellies, gummies, tablets, etc.), noodles (buckwheat, udon, ramen, etc.), dairy products (milk, ice cream, yogurt, etc.), seasonings (miso, soy sauce, etc.), soups, beverages (juice, coffee, black tea, tea, carbonated drinks, sports drinks, etc.), health foods (tablets, capsules, etc.), and nutritional supplements (nutritional drinks, etc.). The transepidermal water loss inhibitor of the present invention may be appropriately blended into these foods and beverages.

[0016] These foods and beverages can contain various ingredients depending on their type, and the following food ingredients can be used: glucose, fructose, sucrose, maltose, sorbitol, stevioside, corn syrup, lactose, citric acid, tartaric acid, malic acid, succinic acid, lactic acid, L-ascorbic acid, dl-α-tocopherol, sodium erythorbate, glycerin, propylene glycol, glycerin fatty acid esters, polyglycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters, gum arabic, carrageenan, casein, gelatin, pectin, agar, B vitamins, nicotinamide, calcium pantothenate, amino acids, calcium salts, colorants, flavorings, and preservatives.

[0017] As a specific manufacturing method, the transepidermal water loss inhibitor is spray-dried or freeze-dried together with powdered cellulose, and then made into a powder, granules, tablets, or solution, which can be easily incorporated into food and drink (instant food, etc.). The transepidermal water loss inhibitor can be dissolved in, for example, fats and oils, ethanol, glycerin, or a mixture thereof to form a liquid, which can be added to beverages or solid foods. If necessary, it can also be mixed with a binder such as gum arabic or dextrin to form a powder or granule, which can be added to beverages or solid foods.

[0018] When the transepidermal water loss inhibitor of the present invention is applied to food or drink, the amount of the active ingredient added is preferably 1 to 20 wt % in total relative to the food or drink.

[0019] The transepidermal water loss inhibitor of the present invention may be used as a material for medicines (including pharmaceuticals and quasi-drugs). It can be produced by appropriately blending the transepidermal water loss inhibitor of the present invention with raw materials for pharmaceutical formulations. Examples of formulation raw materials that can be blended with the transepidermal water loss inhibitor of the present invention include excipients (glucose, lactose, sucrose, sodium chloride, starch, calcium carbonate, kaolin, crystalline cellulose, cacao butter, hardened vegetable oil, kaolin, talc, etc.), binders (distilled water, saline, ethanol water, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, potassium phosphate, polyvinylpyrrolidone, etc.), disintegrants (sodium alginate, agar, charcoal, etc.), and the like. Examples of suitable additives include disintegration inhibitors (sodium bicarbonate, calcium carbonate, sodium lauryl sulfate, stearate monoglyceride, starch, lactose, powdered acacia, gelatin, ethanol, etc.), disintegration inhibitors (white sugar, stearin, cacao butter, hydrogenated oils, etc.), absorption enhancers (quaternary ammonium bases, sodium lauryl sulfate, etc.), adsorbents (glycerin, starch, lactose, kaolin, bentonite, silicic acid, etc.), lubricants (purified talc, stearates, polyethylene glycol, etc.).

[0020] The transepidermal water loss inhibitor of the present invention can be generally administered orally in the form of tablets, pills, soft or hard capsules, fine granules, powders, granules, liquids, etc., but may also be administered parenterally. When administered parenterally, it may be administered in the form of a solution or with the addition of a dispersant, suspending agent, stabilizer, etc., by local tissue administration, intradermal, subcutaneous, intramuscular, or intravenous injection. It may also be in the form of a suppository, etc. Furthermore, it may be administered as an eye drop.

[0021] The dosage may vary depending on the method of administration, the condition, the age of the patient, etc., but typically, adults can be administered 0.5 to 200 mg of the active ingredient per day, and children can be administered 0.5 to 50 mg. The blending ratio of the transepidermal water loss inhibitor can be appropriately changed depending on the dosage form, but it is usually about 0.3 to 15.0 wt% when administered orally or via mucosal absorption, and about 0.01 to 10 wt% when administered parenterally. Note that the dosage varies depending on various conditions, so in some cases a smaller dosage than the above is sufficient, and in other cases it is necessary to administer more than the range.

[0022] The transepidermal water loss inhibitor of the present invention can be expected to have a transepidermal water loss inhibitory effect even when used as an external skin preparation (including cosmetics, pharmaceuticals and quasi-drugs). Examples of the form of external skin preparations that can be blended with the transepidermal water loss inhibitor of the present invention include milky lotion, soap, facial cleanser, bath additive, cream, milky lotion, skin lotion, cologne, shaving cream, shaving lotion, cosmetic oil, suntan / sunscreen lotion, face powder, foundation, perfume, pack, nail cream, enamel, enamel remover, eyebrow pencil, blusher, eye cream, eye shadow, mascara, eyeliner, lipstick, lip balm, shampoo, rinse, hair dye, dispersion, cleanser, etc. Examples of the form of medicines or quasi-drugs that can be blended with the transepidermal water loss inhibitor of the present invention include ointments, creams, external liquids, etc.

[0023] In addition to the transepidermal water loss inhibitor of the present invention, the skin topical preparation in the above form may contain ingredients that are incorporated into skin topical preparations such as cosmetics and quasi-drugs, as long as the transepidermal water loss inhibitory effect is not impaired, such as oils, higher alcohols, fatty acids, ultraviolet absorbers, powders, pigments, surfactants, polyhydric alcohols, sugars, polymers, physiologically active ingredients, solvents, antioxidants, fragrances, preservatives, etc. Examples are listed below, but the present invention is not limited to these examples.

[0024] (1) Example of oil Ester-based oil phase components: glyceryl tri-2-ethylhexanoate, cetyl 2-ethylhexanoate, isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, octyl palmitate, isocetyl isostearate, butyl stearate, butyl myristate, ethyl linoleate, isopropyl linoleate, ethyl oleate, isocetyl myristate, isostearyl myristate, isostearyl palmitate, octyldodecyl myristate, isocetyl isostearate, diethyl sebacate, diisopropyl adipate isopropyl, isoarachyl neopentanoate, tri(caprylic / capric)glyceryl, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentaerythritol tetra-2-ethylhexanoate, cetyl caprylate, decyl laurate, hexyl laurate, decyl myristate, myristyl myristate, cetyl myristate, stearyl stearate, decyl oleate, cetyl ricinoleate, isostearyl laurate, isotridecyl myristate, isocetyl myristate, isostearate Tearyl, isocetyl palmitate, isostearyl palmitate, octyl stearate, isocetyl stearate, isodecyl oleate, octyldodecyl oleate, octyldodecyl linoleate, isopropyl isostearate, cetostearyl 2-ethylhexanoate, stearyl 2-ethylhexanoate, hexyl isostearate, ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicaprate, propylene glycol dicaprylate, propylene glycol dicaprylate, dicaprin Neopentyl glycol acid, neopentyl glycol dioctanoate, glyceryl tricaprylate, glyceryl triundecylate, glyceryl triisopalmitate, glyceryl triisostearate, octyldodecyl neopentanoate, isostearyl octanoate, octyl isononanoate, hexyldecyl neodecanoate, octyldodecyl neodecanoate, isocetyl isostearate, isostearyl isostearate, octyldecyl isostearate, polyglycerin oleate, polyglycerin isostearate, dipropyl carbonate,Dialkyl carbonate (C12-18), triisocetyl citrate, triisoarachyl citrate, triisooctyl citrate, lauryl lactate, myristyl lactate, cetyl lactate, octyldecyl lactate, triethyl citrate, acetyl triethyl citrate, acetyl tributyl citrate, trioctyl citrate, diisostearyl malate, 2-ethylhexyl hydroxystearate, di-2-ethylhexyl succinate, diisobutyl adipate, diisopropyl sebacate propyl, dioctyl sebacate, cholesteryl stearate, cholesteryl isostearate, cholesteryl hydroxystearate, cholesteryl oleate, dihydrocholesteryl oleate, phytosteryl isostearate, phytosteryl oleate, isocetyl 12-stearoylhydroxystearate, stearyl 12-stearoylhydroxystearate, isostearyl 12-stearoylhydroxystearate, and the like. Hydrocarbon-based oil phase components: squalane, liquid paraffin, α-olefin oligomer, isoparaffin, ceresin, paraffin, liquid isoparaffin, polybutene, microcrystalline wax, petrolatum, etc. Animal and vegetable oils and their hydrogenated oils, and naturally derived waxes: beef tallow, hydrogenated beef tallow, lard, hydrogenated lard, horse oil, hydrogenated horse oil, mink oil, orange roughy oil, fish oil, hydrogenated fish oil, egg yolk oil, and other animal oils and their hydrogenated oils, avocado oil, almond oil, olive oil, cocoa butter, kiwi seed oil, apricot kernel oil, kukui nut oil, sesame oil, wheat germ oil, rice germ oil, rice bran oil, safflower oil, shea butter, soybean oil, evening primrose oil, perilla oil, tea seed oil, camellia oil, corn oil, rapeseed oil, Examples of such oils include vegetable oils and their hydrogenated oils such as hydrogenated rapeseed oil, palm kernel oil, hydrogenated palm kernel oil, palm oil, hydrogenated palm oil, peanut oil, hydrogenated peanut oil, castor oil, hydrogenated castor oil, sunflower oil, grape seed oil, jojoba oil, hydrogenated jojoba oil, macadamia nut oil, medicamentoil, cottonseed oil, hydrogenated cottonseed oil, coconut oil, and hydrogenated coconut oil; and waxes such as beeswax, high acid value beeswax, lanolin, reduced lanolin, hydrogenated lanolin, liquid lanolin, carnauba wax, and montan wax. Silicone-based oil phase components: dimethylpolysiloxane, methylphenylpolysiloxane, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dodecamethylcyclosiloxane, methylhydrogenpolysiloxane, polyether-modified organopolysiloxane, dimethylsiloxane-methylcetyloxysiloxane copolymer, dimethylsiloxane-methylstearoxysiloxane copolymer, alkyl-modified organopolysiloxane, terminal-modified organopolysiloxane, amino-modified silicone oil, amino-modified organopolysiloxane, dimethiconol, silicone gel, acrylic silicone, trimethylsiloxysilicate, silicone RTV rubber, etc. Fluorine-based oil phase components: Perfluoropolyether, fluorine-modified organopolysiloxane, fluorinated pitch, fluorocarbon, fluoroalcohol, fluoroalkyl-polyoxyalkylene-co-modified organopolysiloxane, etc.

[0025] (2) Examples of higher alcohols Examples of the alcohol include lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, behenyl alcohol, 2-ethylhexanol, hexadecyl alcohol, and octyldodecanol.

[0026] (3) Examples of fatty acids Examples of the acid include caprylic acid, capric acid, undecylenic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, linoleic acid, linolenic acid, arachidic acid, arachidonic acid, behenic acid, erucic acid, and 2-ethylhexanoic acid.

[0027] (4) Examples of UV absorbers Para-aminobenzoic acid, amyl para-aminobenzoate, dihydroxypropyl ethyl para-aminobenzoate, glyceryl para-aminobenzoate, ethyl para-aminobenzoate, octyl para-aminobenzoate, octyldimethyl para-aminobenzoate, ethylene glycol salicylate, octyl salicylate, triethanolamine salicylate, phenyl salicylate, butylphenyl salicylate, benzyl salicylate, homomenthyl salicylate, benzyl cinnamate, octyl para-methoxycinnamate, 2-ethylhexyl para-methoxycinnamate, glyceryl di-para-methoxycinnamate mono-2-ethylhexanoate, isopropyl para-methoxycinnamate, diethanolamine salt of para-methoxyhydrocinnamate, mixture of diisopropyl and diisopropyl cinnamate, urocanic acid, ethyl urocanate, hydroxymethoxybenzophenone, hydroxymethoxybenzophenone sulfonic acid and its salts, di Hydroxymethoxybenzophenone, dihydroxymethoxybenzophenone sodium disulfonate, dihydroxybenzophenone, dihydroxydimethoxybenzophenone, hydroxyoctoxybenzophenone, tetrahydroxybenzophenone, butylmethoxydibenzoylmethane, 2,4,6-trianilino-p-(carbo-2-ethylhexyl-1-oxy)-1,3,5-triazine, 2-(2-hydroxy-5-methylphenyl)benzotriazole, methyl-O-aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, phenylbenzimidazole sulfate, 3-(4-methylbenzylidene)camphor, isopropyldibenzoylmethane, 4-(3,4-dimethoxyphenylmethylene)-2,5-dioxo-1-imidazolidinepropionate 2-ethylhexyl, and the like, as well as polymer derivatives and silane derivatives thereof.

[0028] (5) Examples of powders and pigments Dyes such as Red No. 104, Red No. 201, Yellow No. 4, Blue No. 1, Black No. 401, lake dyes such as Yellow No. 4 AL Lake, Yellow No. 203 BA Lake, nylon powder, silk powder, urethane powder, Teflon (registered trademark) powder, silicone powder, polymethyl methacrylate powder, cellulose powder, starch, silicone elastomer spherical powder, polyethylene powder and other polymers, yellow iron oxide, red iron oxide, black iron oxide, chromium oxide, carbon black, ultramarine, Prussian blue and other colored pigments, zinc oxide, titanium oxide, acid Examples of such pigments include white pigments such as cerium chloride, extender pigments such as talc, mica, sericite, kaolin, and plate-like barium sulfate, pearl pigments such as titanium mica, metal salts such as barium sulfate, calcium carbonate, magnesium carbonate, aluminum silicate, and magnesium silicate, inorganic powders such as silica and alumina, metal soaps such as aluminum stearate, magnesium stearate, zinc palmitate, zinc myristate, magnesium myristate, zinc laurate, and zinc undecylenate, bentonite, smectite, and boron nitride. There are no particular limitations on the shape (spherical, rod-like, needle-like, plate-like, irregular, flaky, spindle-like, etc.) and particle size of these powders. These powders may or may not have been previously surface-treated by a conventionally known surface treatment, such as a fluorine compound treatment, a silicone treatment, a silicone resin treatment, a pendant treatment, a silane coupling agent treatment, a titanium coupling agent treatment, an oil treatment, an N-acylated lysine treatment, a polyacrylic acid treatment, a metal soap treatment, an amino acid treatment, a lecithin treatment, an inorganic compound treatment, a plasma treatment, or a mechanochemical treatment.

[0029] (6) Examples of surfactants Anionic surfactants: fatty acid soaps, α-acylsulfonates, alkylsulfonates, alkylarylsulfonates, alkylnaphthalenesulfonates, alkyl sulfates, POE alkyl ether sulfates, alkylamide sulfates, alkyl phosphates, POE alkyl phosphates, alkylamide phosphates, alkyloylalkyl taurine salts, N-acylamino acid salts, POE alkyl ether carboxylates, alkylsulfosuccinates, sodium alkylsulfoacetates, acylated hydrolyzed collagen peptide salts, perfluoroalkyl phosphate esters, and the like. Cationic surfactants: alkyltrimethylammonium chloride, stearyltrimethylammonium chloride, stearyltrimethylammonium bromide, cetostearyltrimethylammonium chloride, distearyldimethylammonium chloride, stearyldimethylbenzylammonium chloride, behenyltrimethylammonium bromide, benzalkonium chloride, behenic acid amidopropyldimethylhydroxypropylammonium chloride, stearate diethylaminoethylamide, stearate dimethylaminopropylamide, lanolin derivative quaternary ammonium salts, etc. Amphoteric surfactants: Examples of amphoteric surfactants include carboxybetaine type, amidobetaine type, sulfobetaine type, hydroxysulfobetaine type, amidosulfobetaine type, phosphobetaine type, aminocarboxylate type, imidazoline derivative type, and amidoamine type. Nonionic surfactants: Propylene glycol fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, sorbitan fatty acid esters, POE sorbitan fatty acid esters, POE sorbit fatty acid esters, POE glycerin fatty acid esters, POE alkyl ethers, POE fatty acid esters, POE hydrogenated castor oil, POE castor oil, POE·POP copolymers, POE·POP alkyl ethers, polyether modified silicone lauric acid alkanolamide, alkylamine oxide, hydrogenated soybean phospholipids, etc. Natural surfactants: Examples include lecithin, saponin, sugar-based surfactants, etc.

[0030] (7) Examples of polyhydric alcohols and sugars Examples of suitable sugars include ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, glycerin, diglycerin, polyglycerin, 3-methyl-1,3-butanediol, 1,3-butylene glycol, sorbitol, mannitol, raffinose, erythritol, glucose, sucrose, fructose, xylitol, lactose, maltose, maltitol, trehalose, alkylated trehalose, mixed isomerized sugar, sulfated trehalose, pullulan, etc. Chemically modified versions of these sugars may also be used.

[0031] (8) Examples of polymers Acrylic acid ester / methacrylic acid ester copolymer (Plussize, manufactured by GOO Chemical Co., Ltd.), vinyl acetate / crotonic acid copolymer (Resin 28-1310, manufactured by NSC Co., Ltd.), vinyl acetate / crotonic acid / vinyl neodecanoate copolymer (28-2930, manufactured by NSC Co., Ltd.), methyl vinyl ether maleic acid half ester (Gantrez ES, manufactured by ISP Co., Ltd.), t-butyl acrylate / ethyl acrylate / methacrylic acid copolymer (Rubymer, manufactured by BASF Co., Ltd.), vinyl pyrrolidone / vinyl acetate / vinyl propionate copolymer (Ruviscol VAP, manufactured by BASF Co., Ltd.), vinyl acetate Vinyl acetate / crotonic acid copolymer (Rubyset CA, BASF), vinyl acetate / crotonic acid / vinyl pyrrolidone copolymer (Rubyset CAP, BASF), vinyl pyrrolidone / acrylate copolymer (Rubyflex, BASF), acrylate / acrylamide copolymer (Ultrahold, BASF), vinyl acetate / butyl maleate / isobornyl acrylate copolymer (Advantage, ISP), carboxyvinyl polymer (Carbopol, BFGoodrich), acrylic acid / alkyl methacrylate copolymer (Pemulen, BF Examples of such polymers include anionic polymers such as acetic acid amphoteric product of dialkylaminoethyl methacrylate polymer (Yukaformer, manufactured by Mitsubishi Chemical Corporation) and amphoteric polymers such as octylacrylamide acrylate / hydroxypropyl acrylate / butylaminoethyl methacrylate copolymer (AMPHOMER, manufactured by NSC Corporation); cationic polymers such as quaternary product of vinylpyrrolidone / dimethylaminoethyl methacrylate (GAFQUAT, manufactured by ISP Corporation) and methylvinylimidazolium chloride / vinylpyrrolidone copolymer (Rubycoat, manufactured by BASF Corporation); and nonionic polymers such as polyvinylpyrrolidone (Ruviscol K, manufactured by BASF Corporation), vinylpyrrolidone / vinyl acetate copolymer (Ruviscol VA, manufactured by BASF Corporation), vinylpyrrolidone / dimethylaminoethyl methacrylate copolymer (copolymer 937, manufactured by ISP Corporation), and vinylcaprolactam / vinylpyrrolidone / dimethylaminoethyl methacrylate copolymer (copolymer VC713, manufactured by ISP Corporation).Also suitable for use are naturally occurring polymeric compounds such as cellulose or derivatives thereof, keratin and collagen or derivatives thereof, calcium alginate, pullulan, agar, gelatin, tamarind seed polysaccharides, xanthan gum, carrageenan, high methoxyl pectin, low methoxyl pectin, guar gum, gum arabic, crystalline cellulose, arabinogalactan, karaya gum, tragacanth gum, alginic acid, albumin, casein, curdlan, gellan gum, and dextran.

[0032] (9) Examples of physiologically active ingredients Examples of the physiologically active ingredient include substances that impart some physiological activity to the skin when applied to the skin. For example, they include whitening ingredients, immune activators, anti-aging agents, UV protection agents, slimming agents, tightening agents, antioxidants, hair growth agents, hair restorers, moisturizers, blood circulation promoters, antibacterial agents, bactericides, drying agents, cooling agents, warming agents, vitamins, amino acids, wound healing promoters, irritation relievers, analgesics, cell activators, enzyme ingredients, etc. Examples of suitable ingredients include angelica extract, avocado extract, amacha extract, althea extract, arnica extract, aloe extract, apricot extract, apricot kernel extract, ginkgo extract, fennel extract, turmeric extract, oolong tea extract, eijitsu extract, echinacea leaf extract, scutellaria extract, phellodendron bark extract, coptis japonica extract, barley extract, hypericum extract, white nettle extract, watercress extract, orange extract, Dried seawater, seaweed extract, hydrolyzed elastin, hydrolyzed wheat powder, hydrolyzed silk, chamomile extract, carrot extract, artemisia capillaris extract, licorice extract, kalkade extract, kakyoku extract, cinchona extract, cucumber extract, guanosine, gardenia extract, kumazasa extract, sophora flavescens extract, walnut extract, grapefruit extract, clematis extract, chlorella extract, mulberry extract, gentiana extract, black tea extract, yeast extract, burdock extract, coix seed extract, Fermented rice bran extract, rice germ oil, comfrey extract, collagen, lingonberry extract, Chinese ivy extract, Chinese rhizome extract, umbilical cord extract, salvia extract, soapwort extract, bamboo extract, hawthorn extract, Japanese pepper extract, shiitake mushroom extract, rehmannia extract, lithospermum extract, perilla extract, linden extract, meadowsweet extract, peony extract, calamus root extract, white birch extract, horsetail extract, ivy extract, hawthorn extract, se Elderberry extract, yarrow extract, peppermint extract, sage extract, mallow extract, cnidium extract, swertia britannica extract, soybean extract, tsinga extract, thyme extract, tea extract, clove extract, imperata cylindrica extract, tangerine peel extract, angelica extract, calendula extract, peach kernel extract, spruce extract, houttuynia cordata extract, tomato extract, natto extract, carrot extract, garlic extract, wild rose extract, hibiscus extract,Examples of such extracts include burdock root extract, parsley extract, honey, witch hazel extract, parietaria extract, burdock root extract, bisabolol, loquat extract, coltsfoot extract, butterbur bud extract, poria extract, butcher's broom extract, grape extract, propolis, loofah extract, safflower extract, peppermint extract, linden extract, peony extract, hop extract, pine extract, horse chestnut extract, skunk cabbage extract, soapberry extract, melissa extract, peach extract, cornflower extract, eucalyptus extract, saxifrage extract, coix seed extract, mugwort extract, lavender extract, apple extract, lettuce extract, lemon extract, astragalus extract, rose extract, rosemary extract, Roman chamomile extract, and royal jelly extract. In addition, it contains biopolymers such as deoxyribonucleic acid, mucopolysaccharides, sodium hyaluronate, sodium chondroitin sulfate, collagen, elastin, chitin, chitosan, and hydrolyzed eggshell membrane, moisturizing ingredients such as amino acids, hydrolyzed peptides, sodium lactate, urea, sodium pyrrolidone carboxylate, betaine, whey, and trimethylglycine, oily ingredients such as sphingolipids, ceramides, phytosphingosine, cholesterol, cholesterol derivatives, and phospholipids, ε-aminocaproic acid, glycyrrhizic acid, β-glycyrrhetinic acid, lysozyme chloride, and guaiazure. immune stimulants such as glycerin, hydrocortisone, etc.; vitamins such as vitamin A, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, calcium pantothenate, biotin, nicotinamide, vitamin C ester, etc.; active ingredients such as allantoin, diisopropylamine dichloroacetate, 4-aminomethylcyclohexanecarboxylic acid, etc.; antioxidants such as tocopherol, carotenoids, flavonoids, tannins, lignans, saponins, etc.; cell stimulants such as alpha-hydroxy acids, beta-hydroxy acids, etc.; blood circulation promoters such as gamma-oryzanol, vitamin E derivatives, etc. Wound healing agents such as retinol and retinol derivatives, skin whitening agents such as arbutin, kojic acid, placenta extract, sulfur, ellagic acid, linoleic acid, tranexamic acid, and glutathione, cepharanthine, licorice extract, capsicum tincture, hinokitiol, iodized garlic extract, pyridoxine hydrochloride, DL-α-tocopherol, DL-α-tocopherol acetate, nicotinic acid, nicotinic acid derivatives, calcium pantothenate, D-pantothenyl alcohol, acetyl pantothenyl ethyl ether, biotin, allantoin, isopropyl methylphenol, estradiol, All, ethinyl estradiol, capronium chloride, benzalkonium chloride, diphenhydramine hydrochloride, tacanal, camphor, salicylic acid, vanillylamide nonylate, vanillylamide nonanoate, piroctone olamine, glyceryl pentadecanoate, L-menthol, mononitroguaiacol, resorcinol, gamma-aminobutyric acid, benzethonium chloride, mexiletine hydrochloride, auxin, female hormones, cantharides tincture, cyclosporine, zinc pyrithione, hydrocortisone, minoxidil, polyoxyethylene sorbitan monostearate, peppermint oil,Examples include hair growth agents such as Sasanishiki extract.

[0033] (10) Examples of antioxidants Examples of antioxidants include sodium bisulfite, sodium sulfite, erythorbic acid, sodium erythorbate, dilauryl thiodipropionate, tocopherol, tolylbiguanide, nordihydroguaiaretic acid, parahydroxyanisole, butylhydroxyanisole, dibutylhydroxytoluene, ascorbyl stearate, ascorbyl palmitate, octyl gallate, propyl gallate, carotenoids, flavonoids, tannins, lignans, saponin, and plant extracts such as apple extract and clove extract that have antioxidant effects.

[0034] (11) Examples of solvents Examples of suitable solvents include purified water, ethanol, lower alcohols, ethers, LPG, fluorocarbons, N-methylpyrrolidone, fluoroalcohols, volatile linear silicones, and next-generation fluorocarbons.

[0035] The transepidermal water loss inhibitor of the present invention can be used as a raw material for food and drink compositions, pharmaceutical compositions, and external skin preparations. The pharmaceutical raw materials that can be blended with these can be the same as those used in the transepidermal water loss inhibitor described above, and the manufacturing and administration methods can also be the same as those for the transepidermal water loss inhibitor. EXAMPLES

[0036] Examples of the present invention will be described below. Note that the following examples are described to confirm various actions and effects of the transepidermal water loss inhibitor obtained by the present invention, and the scope of the present invention is not limited to these products and manufacturing methods.

[0037] Working Example (1) Isolation of the lactic acid bacteria Kuzunotsuru The "Kuzunotsuru lactic acid bacteria" belonging to Leuconostoc mesenteroides was isolated by the following procedure. Kudzu vines are enriched in a liquid medium for lactic acid bacteria containing antibiotics at 25℃ to 37℃ for 24 to 48 hours. The obtained culture medium was smeared on plate count agar medium supplemented with BCP, and five novel strains belonging to Leuconostoc mesenteroides were selected. The "Kuzunotsuru lactic acid bacteria" belonging to Leuconostoc mesenteroides obtained as described above was deposited at the National Institute of Technology and Evaluation, Biotechnology Center, Patent Organism Depositary (NITE-IPOD) on July 11, 2018 (accession number NITE P-02751). (2) 16S rDNA gene analysis of "Kuzunotsuru Lactic Acid Bacteria" The base sequence of the 16S rDNA gene of the isolated "Kuzunotsuru Lactic Acid Bacteria" was determined. The results are shown in Figure 8 (Sequence No. 1). Figure 9 shows an alignment comparing the 16S rDNA gene of the "Kuzunotsuru Lactic Acid Bacteria" strain (SIID23149-01 in the upper row, Sequence No. 1) with the comparative strain RIB.9186 belonging to Leuconostoc mesenteroides (obtained from the National Research Institute of Brewing, SIID23149-02 in the lower row, Sequence No. 2). Figure 10 is a simplified molecular phylogenetic tree based on the nucleic acid sequence of the 16S rDNA gene of "Kuzunotsuru Lactobacillus." The line in the upper left corner is a scale bar, the numbers at the branches of the phylogenetic branches are bootstrap values, and the "T" at the end of the strain name indicates the type strain of that species.

[0038] Test Example 1: Transepidermal Water Loss (TEWL) Evaluation of "Kuzunotsuru Lactic Acid Bacteria" Test Method Hairless mice were orally administered "Kuzunotsuru Lactobacillus casei" powder (Patent Microorganisms Deposit Center Accession Number: NITE NITE P-02751) (50 or 100 mg / kg) for 28 days, and the TEWL of the dorsal skin was measured. After that, a sodium dodecyl sulfate solution (SDS solution) was applied to the right side across the midline for 5 minutes and then wiped clean. This procedure was repeated for a total of 3 days, and the TEWL was measured again the day after. The skin was also sampled the following day to examine the mRNA expression levels of involucrin, filaggrin, and transglutaminase 1. The results are shown in Figure 1 (before SDS application), Figure 2 (after SDS application), Figure 3 (changes before and after SDS application), and Figure 4 (difference between the application site and the non-application site after SDS application). Figure 5 shows the expression level of involucrin, Figure 6 shows the expression level of filaggrin, and Figure 7 shows the expression level of transglutaminase 1. These are proteins present in the cornified envelope of the stratum corneum; involucrin promotes the keratinization of epidermal cells, filaggrin binds to keratin to strengthen the stratum corneum, and transglutaminase 1 promotes the cross-linking of keratinous proteins.

[0039] Measurement results and effects of the embodiment in Test Example 1 As shown in Figures 1 and 2, it was confirmed that TEWL was suppressed by administration of "Kuzunotsuru Lactic Acid Bacteria", especially at the SDS application site. In addition, as shown in Figure 3, it was confirmed that the TEWL suppression effect was excellent in a concentration-dependent manner at the SDS application site. In addition, as shown in Figure 4, when the difference between the SDS application site and the non-application site was examined, it was found that TEWL was significantly reduced at 100 mg / kg administration compared to the control. Furthermore, as shown in Figures 5 and 7, the expression levels of involucrin and transglutaminase 1 were significantly increased, and the expression level of filaggrin also showed an increasing trend as shown in Figure 6, so it is considered that "Kuzunotsuru Lactic Acid Bacteria" increases the expression level of stratum corneum proteins involved in moisturizing and barrier function. From the above, it was confirmed that "Kuzunotsuru Lactobacillus" is useful as a TEWL inhibitor, and therefore useful as a moisturizer. In addition, since TEWL was particularly suppressed in the SDS application area, it was also confirmed to be useful as an agent for improving rough skin.

[0040] Test Example 2: Clinical trial of "Kuzunotsuru Lactic Acid Bacteria" 1. Study Overview -Exam period: 5 / 14-6 / 25 (6 weeks) Subjects: 27 (20 men, 8 women) Study design: Double-blind comparative study (placebo group: 14 people, lactobacillus group: 14 people) One woman in the placebo group dropped out due to ill health. Testing method: Salivary IgA, dermal collagen density, TEWL (transepidermal water loss), and questionnaire (questionnaire regarding skin quality). The above dermal collagen density was measured by measuring the collagen score (Dermalabo's registered trademark) (Dermalabo indicates the density of collagen in the dermis. The higher the value, the more abundant the collagen and the better the condition of the dermal collagen). *The questionnaire was created based on the article entitled "Effects of taking lactic acid bacteria fermentation filtrate PS-B1 on bowel movements, stool characteristics, and skin quality" published in the Journal of the Japanese Society for Food and Nutrition, Vol. 30, No. 3, pp. 112-122 (2020), and participants were asked to fill out the form shown in Table 1 below. The results are shown in Figure 11 (TEWL (cheek)), Figure 12 (TEWL (arm)), Figure 13 (saliva IgA), Figure 14 (change in DermaLab (collagen score)), and Table 2 (skin quality questionnaire). [Table 1]

[0041] [Table 2]

[0042] Results and Effects of the Examples in Test Example 2 (1) Transepidermal water loss (TEWL) (cheek) As shown in Figure 11, both the placebo group and the lactobacillus intake group showed a significant decrease after 4 weeks (4W) and 6 weeks (6W) of intake compared to before intake (0W) in each group. There was no significant difference between the groups, but the lactobacillus intake group showed a greater tendency for improvement. This confirmed that Kuzunotsuru lactobacillus has an effect of improving TEWL in the cheeks. (2) Transepidermal water loss (TEWL) (arm) As shown in Figure 12, compared to before intake (0W), both the placebo group and the lactobacillus intake group showed a significant decrease at 4W and 6W intake within each group. Although there was no significant difference between the groups, there was a tendency for improvement in the lactobacillus intake group. This confirmed that Kuzunotsuru lactobacillus has an effect of improving TEWL in the arms as well. (3) Salivary IgA As shown in Figure 13, only in the lactobacillus intake group, IgA levels increased significantly at 4W compared to before intake (0W). Although there was no significant difference between the groups, there was a tendency for IgA to increase in the lactobacillus intake group (see Figure 13). This confirmed that Kuzunotsuru lactobacillus has the effect of increasing IgA. (4) DermaLab (Dermal Collagen Density) As shown in FIG. 14, the collagen score, which is an index showing the density of dermal collagen, was significantly increased at both 4W and 6W compared to before intake (0W) only in the lactic acid bacteria intake group. In addition, although there was no significant difference between the groups, an increasing trend was observed in the lactobacillus intake group. This confirmed that Kuzunotsuru lactobacillus has the effect of improving the density of dermal collagen.

[0043] (5) Questionnaire (skin type-related) As shown in Table 2, in the category of "glowing skin," only the lactic acid bacteria intake group showed significant improvement at 4W compared to before intake (0W), and there was also a tendency for improvement at 6W. Additionally, in the category of "firm skin," only the lactic acid bacteria intake group showed a significant improvement at 6W compared to before intake (0W). Additionally, in the category of "even skin tone," only the lactic acid bacteria intake group showed a tendency for improvement at 4W compared to before intake (0W). Furthermore, in the category of "skin that is not sticky," although there was no significant difference in the lactic acid bacteria group, the condition worsened in the placebo group, whereas there was no change in the lactic acid bacteria group, so it can be said that there was a tendency for improvement when compared with the placebo. In addition, in the category of "skin that is not bothered by dryness," only the lactobacillus intake group showed significant improvement at 4W and 6W compared to before intake (0W). These results confirmed that Kuzunotsuru lactobacillus has the effect of improving skin quality.

[0044] The above results confirmed that Kuzunotsuru Lactic Acid Bacteria has a dual barrier function for both the skin and the immune system, in addition to improving transepidermal water loss (TEWL) and collagen density, and increasing salivary IgA, as determined by a questionnaire (related to skin type).

[0045] The following are examples of formulations of the transepidermal water loss inhibitor (Kuzunotsuru lactic acid bacteria) according to the present invention. Note that the following formulation examples do not limit the present invention. Formulation example 1: Chewing gum Sugar 53.0wt% Gum base 20.0 Glucose 10.0 Starch syrup 16.0 Fragrance 0.5 Transepidermal water loss inhibitor 0.5 100.0wt%

[0046] Mixture Example 2: Gummies Reduced starch syrup 40.0wt% Granulated sugar 20.0 Glucose 20.0 Gelatin 4.7 Wednesday 9.68 Yuzu juice 4.0 Yuzu flavor 0.6 Dye 0.02 Transepidermal water loss inhibitor 1.0 100.0wt%

[0047] Mixture example 3: Candy Sugar 50.0wt% Syrup 33.0 Wednesday 14.4 organic acid 2.0 Fragrance 0.2 Transepidermal water loss inhibitor 0.4 100.0wt%

[0048] Mixture example 4: Yogurt (hard / soft) Milk 41.5wt% Skim milk powder 5.8 Sugar 8.0 Agar 0.15 Gelatin 0.1 Lactic acid bacteria 0.005 Transepidermal water loss inhibitor 0.4 fragrance trace amount water residue 100.0wt%

[0049] Formulation example 5: Soft drink Fructose glucose liquid sugar 30.0wt% Emulsifier 0.5 Transepidermal water loss inhibitor 0.3 Fragrance (appropriate amount) Purified water remainder 100.0wt%

[0050] Formulation example 6: Tablet confectionery Sugar 76.4wt% Glucose 19.0 Sucrose fatty acid ester 0.2 Transepidermal water loss inhibitor 0.5 Purified water 3.9 100.0wt%

[0051] Formulation example 7: Soft capsule Brown rice germ oil 47.0wt% Yuzu seed oil 40.0 Emulsifier 12.0 Transepidermal water loss inhibitor 1.0 100.0wt%

[0052] Formulation Example 8: Tablets Lactose 54.0wt% Crystalline cellulose 30.0 Starch decomposition product 10.0 Glycerin fatty acid ester 5.0 Transepidermal water loss inhibitor 1.0 100.0wt%

[0053] Formulation example 9: Cosmetic cream Squalane 20.0wt% Beeswax 5.0 Refined Jojoba Oil 5.0 Glycerin 5.0 Glycerin Monostearate 2.0 Polyoxyethylene (20) Sorbitan- Monostearate 2.0 Transepidermal water loss inhibitor 2.0 Preservatives (appropriate amount) Fragrance (appropriate amount) Purified water remainder 100.0wt%

[0054] Formulation example 10: Lotion Ethanol 5.0wt% Glycerin 2.0 1,3-Butylene glycol 2.0 Polyethylene oleyl ether 0.5 Sodium citrate 0.1 Citric acid 0.1 Transepidermal water loss inhibitor 0.1 Purified water remainder 100.0wt%

[0055] Formulation example 11: Body gel Macadamia nut oil 2.0wt% Octyldodecyl myristate 10.0 Methylphenylpolysiloxane 5.0 Behenyl Alcohol 3.0 Stearic Acid 3.0 Batyl alcohol 1.0 Glyceryl Monostearate 1.0 Polyoxyethylene sorbitol tetraoleate 2.0 Hydrogenated soy phospholipids 1.0 Ceramide 0.1 Retinol Palmitate 0.1 Preservatives (appropriate amount) Centella asiatica extract 1.0 Transepidermal water loss inhibitor 1.0 1,3-Butylene glycol 5.0 Purified water remainder 100.0wt%

[0056] Formulation example 12: Emulsion Squalane 4.0wt% Vaseline 2.5 Cetanol 2.0 Glycerin 2.0 Lipophilic glyceryl monostearate 1.0 Stearic acid 1.0 L-Arginine 1.0 Transepidermal water loss inhibitor 0.5 Potassium hydroxide 0.1 fragrance trace amount Purified water remainder 100.0wt%

[0057] Formulation example 13: Bath additive (liquid) Propylene glycol 50.0wt% Ethanol 20.0 Sodium sulfate 5.0 Transepidermal water loss inhibitor 0.5 Lanolin 0.5 Avocado oil 0.5 Dye 1.5 Fragrance 22.0 100.0wt% [Industrial Applicability]

[0058] As described above, the present invention can provide a novel transepidermal water loss inhibitor. [Accession number]

[0059] The “Tsuru 5” strain, belonging to Leuconostoc mesenteroides, was deposited at the National Institute of Technology and Evaluation, Biotechnology Center, Intellectual Property Organism Depositary (NITE-IPOD) on July 11, 2018 (accession number NITE P-02751). [Sequence List Free Text]

[0060] SEQ ID NO: 1: Nucleic acid sequence of the 16S rDNA gene of the "Tsuru 5" strain SEQ ID NO: 2: Nucleic acid sequence of the 16S rDNA gene of strain RIB.9186 belonging to Leuconostoc mesenteroides

Claims

1. A transepidermal water loss inhibitor comprising a lactic acid bacterium (Leuconostoc mesenteroides) strain (Patent Microorganisms Deposit Center Accession Number: NITE P-02751) as an active ingredient.

2. A skin roughness improving agent comprising the transepidermal water loss inhibitor according to claim 1 as an active ingredient.

3. A stratum corneum moisturizing and barrier protein expression promoter containing a lactic acid bacterium (Leuconostoc mesenteroides) strain derived from kudzu vine (Patent Microorganisms Deposit Center Accession Number: NITE P-02751) as an active ingredient.

Images